Schlaich MP, Bellet M, Weber MA et al (2022) Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400:1927–1937. https://doi.org/10.1016/S0140-6736(22)02034-7

Article  CAS  PubMed  Google Scholar 

Clozel M (2022) Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol 100:573–583. https://doi.org/10.1139/cjpp-2022-0010

Article  CAS  PubMed  Google Scholar 

Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415. https://doi.org/10.1038/332411a0

Article  ADS  CAS  PubMed  Google Scholar 

Iglarz M, Clozel M (2010) At the heart of tissue: endothelin system and end-organ damage. Clin Sci 119:453–463. https://doi.org/10.1042/CS20100222

Article  CAS  Google Scholar 

Schiffrin EL (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14. https://doi.org/10.1016/s0895-7061(01)02074-x. :83S-89S

Trensz F, Bortolamiol C, Kramberg M et al (2019) Pharmacological characterization of Aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the Renin Angiotensin System, in two models of experimental hypertension. J Pharmacol Exp Ther 368:462–473. https://doi.org/10.1124/jpet.118.253864

Article  CAS  PubMed  Google Scholar 

Verweij P, Danaietash P, Flamion B et al (2020) Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension 75:956–965

Article  CAS  PubMed  Google Scholar 

Sidharta P, Melchior M, Kankam MK, Dingemanse J (2019) Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Devel Ther Volume 13:949–964. https://doi.org/10.2147/DDDT.S199051

Article  CAS  Google Scholar 

Sidharta PN, Fischer H, Dingemanse J (2021) Absorption, distribution, metabolism, and excretion of Aprocitentan, a dual endothelin receptor antagonist, in humans. Curr Drug Metab 22:399–410. https://doi.org/10.2174/1389200222666210204202815

Article  CAS  PubMed  Google Scholar 

Sidharta PN, Ulč I, Dingemanse J (2019) Single-dose pharmacokinetics and tolerability of Aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment. Clin Drug Investig 39:1117–1123. https://doi.org/10.1007/s40261-019-00837-x

Article  CAS  PubMed  Google Scholar 

Fontes MSC, Dingemanse J, Halabi A et al (2022) Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep 12:19067. https://doi.org/10.1038/s41598-022-22470-z

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Sidharta PN, Dingemanse J (2020) Effect of multiple-dose Aprocitentan Administration on the pharmacokinetics of midazolam in healthy male subjects. Eur J Drug Metab Pharmacokinet 45:227–234. https://doi.org/10.1007/s13318-019-00590-8

Article  CAS  PubMed  Google Scholar 

Sidharta PN, Dingemanse J (2020) Effects of multiple-dose administration of Aprocitentan on the pharmacokinetics of Rosuvastatin. Clin Pharmacol Drug Dev 9:995–1002. https://doi.org/10.1002/cpdd.815

Article  CAS  PubMed  Google Scholar 

Fontes MSC, Dingemanse J, Sidharta PN (2021) Multiple-dose pharmacokinetics, Safety, and tolerability of Aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and caucasian subjects. Clin Pharmacol Drug Dev 10:718–725. https://doi.org/10.1002/cpdd.881

Article  CAS  PubMed  Google Scholar 

Raebel MA, Ellis JL, Carroll NM et al (2012) Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 27:57–64. https://doi.org/10.1007/s11606-011-1829-z

Article  PubMed  Google Scholar 

Gueneau de Mussy P, Sidharta PN, Wuerzner G et al (2021) Effects of the dual endothelin receptor antagonist Aprocitentan on Body Weight and Fluid Homeostasis in healthy subjects on a high Sodium Diet. Clin Pharmacol Ther 109:746–753. https://doi.org/10.1002/cpt.2043

Article  CAS  PubMed  Google Scholar 

Sidharta PN, Brussee JM, Schultz A et al (2022) ACCP Abstract Booklet. Clin Pharmacol Drug Dev 11:1–112. https://doi.org/10.1002/cpdd.1151

Article  Google Scholar 

Idorsia Pharmaceuticals Ltd (2022) Bioequivalence Study of Different Aprocitentan Tablet Formulations. In: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05196399. Accessed 26 Jun 2023

Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504. https://doi.org/10.1023/A:1012299115260

Article  CAS  PubMed  Google Scholar 

Lixoft (2021) Monolix documentation

Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27:94–128

Article  MathSciNet  Google Scholar 

Levey AS, Bosch JP, Breyer Lewis J et al (1999) A more Accurate Method to Estimate glomerular filtration rate from serum creatinine: a New Prediction equation. Ann Intern Med 130:461. https://doi.org/10.7326/0003-4819-130-6-199903160-00002

Article  CAS  PubMed  Google Scholar 

Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. https://doi.org/10.7326/0003-4819-145-4-200608150-00004

Article  PubMed  Google Scholar 

Ayral G, Si Abdallah J, Magnard C, Chauvin J (2021) A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: the COSSAC approach. CPT Pharmacometrics Syst Pharmacol 10:318–329. https://doi.org/10.1002/psp4.12612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delattre M, Lavielle M, Poursat MA (2014) A note on BIC in mixed-effects models. Electron J Stat 8:456–475. https://doi.org/10.1214/14-EJS890

Article  MathSciNet  Google Scholar 

Krause A, Lowe P (2014) Visualization and communication of pharmacometric models with Berkeley Madonna. CPT Pharmacometrics Syst Pharmacol 3:116. https://doi.org/10.1038/psp.2014.13

Article  CAS  Google Scholar 

Marcoline FV, Furth J, Nayak S et al (2022) Berkeley Madonna Version 10–A simulation package for solving mathematical models. CPT Pharmacometrics Syst Pharmacol 11:290–301. https://doi.org/10.1002/psp4.12757

Article  CAS  PubMed  PubMed Central  Google Scholar 

R (2020) R: a Language and Environment for Statistical Computing. Version 3.6.1 and 4.0.4, 2002, R Foundation for Statistical Computing